Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. ESMO Videos

TalaCom: Talazoparib + Axitinib for DDR-mutated Cancers or BRCA1/2 wild-type Ovarian Cancer

Login to get immediate access to this content.

Login

Speaker: Natalie Yan Li Ngoi, National University Health System, Singapore

Abstract discussed:

The speakers and studies featured in this video series were selected independently by ESMO.

Published April 2025

Related Links

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.